ELMWOOD PARK, N.J., August 18, 2020 – BioReference Laboratories Inc., an OPKO Health Company, is pleased to announce it is now in-network with all Blue Cross and Blue Shield of Texas (BCBSTX) products, including its Health Maintenance Organization (HMO) and Medicaid lines of business. The contract includes BioReference’s subsidiary GeneDx, Inc., a full service genetics laboratory.
“Becoming an in-network provider reiterates BioReference’s commitment to providing Blue Cross and Blue Shield of Texas members lower laboratory costs, more choices built on our legacy of accurate and timely results,” said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. “BioReference’s in-network status comes during a time when the significance of laboratory testing to patients is critically important.”
The agreement went into effect on August 15, 2020.
About BioReference Laboratories, Inc.
BioReference provides comprehensive testing to physicians, clinics, hospitals, employers, government units, correctional institutions and medical groups. BioReference has been working expeditiously to develop and offer test services that will yield high quality and accurate results, including a molecular test for helping with COVID-19 diagnosis and a serology test to help indicate possible COVID-19 exposure. The company is in network with the five largest health plans in the United States, operates a network of 11 laboratory locations, and is backed by a medical staff of more than 120 M.D., Ph.D. and other professional level clinicians and scientists. With a leading position in the areas of genetics, women’s health, maternal fetal medicine, oncology and urology, BioReference and its specialty laboratories, GenPath and GeneDx, are advancing the course of modern medicine. For more information, visit www.bioreference.com.
About OPKO Health, Inc.
OPKO is a multinational biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large, rapidly growing markets by leveraging its discovery, development, and commercialization expertise and novel and proprietary technologies. For more information, visit www.opko.com.
Media contact for BioReference Laboratories:
Hillary Titus, htitus@bioreference.com
